Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

everolimus

- PMLiVE

Novartis gets EU nod for leukaemia drug Rydapt

The FLT3 inhibitor adds to its US approval in AML

Bristol-Myers Squibb (BMS) building

NICE says OK to Opdivo for lung cancer via CDF

Comes after BMS drops the price of its PD-1 inhibitor

- PMLiVE

Roche faces prospect of second Rituxan biosimilar in US

FDA begins its review of Sandoz's version of the immunotherapy treatment

Novartis looks outside pharma for digital transformation

Appoints former Sainsbury's Argos executive Bertrand Bodson

- PMLiVE

Novartis scores but Roche misses in melanoma trials

Phase III trial combo success for Tafinlar/Mekinist “unprecedented”

- PMLiVE

NICE: We’re the institute of ‘yes’

But Meindert Boysen says affordability conversations with pharma need to happen earlier

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo and Yervoy ace kidney cancer trial

Combined checkpoint inhibitors show improved survival versus standard therapy

- PMLiVE

Takeda can’t sway NICE on oral myeloma therapy Ninlaro

Drug not recommended for NHS use in England and Wales

- PMLiVE

Cellectis floored by patient death in CAR-T trial

FDA puts two cancer immunotherapy trials on hold

- PMLiVE

Vas Narasimhan takes top Novartis job on Jimenez departure

The soon-to-be CEO will take over at a time when the company has a strong pipeline

- PMLiVE

Novartis claims first CAR-T approval, setting $475k price tag

Kymriah receives FDA nod to treat ALL patients

- PMLiVE

NICE backs Europe’s first stem cell therapy

Holoclar is approved for routine use in patients with LSCD

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links